{"id":71484,"date":"2026-05-20T10:05:00","date_gmt":"2026-05-20T10:05:00","guid":{"rendered":"https:\/\/medsbase.com\/pnc-27\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"pnc-27","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/pnc-27\/","title":{"rendered":"PNC-27 (Pept\u00eddeo Quim\u00e9rico de Membrana Direcionado para p53-HDM2)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 PNC-27?<\/h3>\n<p style=\"margin: 0;\"><strong>PNC-27<\/strong> \u00e9 um pept\u00eddeo quim\u00e9rico sint\u00e9tico (~32 amino\u00e1cidos) desenvolvido no Albert Einstein College of Medicine (Bowne, Pinto, Michl, Rauschmayer, Brower et\u00a0al.) que funde dois dom\u00ednios funcionais: uma <strong>h\u00e9lice de liga\u00e7\u00e3o a HDM2<\/strong> derivado dos res\u00edduos 12\u201326 do dom\u00ednio de transativa\u00e7\u00e3o da p53 (sequ\u00eancia PPLSQETFSDLWKLL) e um <strong>pept\u00eddeo de resid\u00eancia de membrana (MRP)<\/strong> anexado para ancorar e romper as membranas plasm\u00e1ticas de c\u00e9lulas cancer\u00edgenas. A premissa mecanicista \u00e9 que a HDM2 (o hom\u00f3logo humano do MDM2) \u00e9 expressa anormalmente na <em>superf\u00edcie da membrana plasm\u00e1tica<\/em> of cancer cells \u2014 not just in the nucleus where it normally degrades p53. PNC-27 binds the surface-exposed HDM2, the MRP domain then disrupts the lipid bilayer, and cancer cells undergo rapid membrane lysis and necrotic cell death. Published in pancreatic, leukaemia, breast cancer, and other tumour models. For clinical studies use only. <em>Pept\u00eddeo quim\u00e9rico disruptor de membrana direcionado a tumores.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pept\u00eddeo quim\u00e9rico sint\u00e9tico ~32-aa; pept\u00eddeo terap\u00eautico disruptor de membrana direcionado a tumores; h\u00e9lice de liga\u00e7\u00e3o a HDM2 + pept\u00eddeo quim\u00e9rico de resid\u00eancia de membrana (MRP)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">PNC-27 (Peptide Nuclear Construct 27; sin\u00f4nimos: quimera p53-MRP, constructo p53(12-26)-MRP)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pharmaceutical-grade chimeric peptide \u2014 no single canonical CAS; identification by published sequence and supplier COA<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H\u00e9lice de liga\u00e7\u00e3o a HDM2 no terminal N (res\u00edduos 12\u201326 da transativa\u00e7\u00e3o da p53): <strong>PPLSQETFSDLWKLL<\/strong>; linker; C-terminal membrane-residency peptide (MRP, sequence varies slightly across published references \u2014 users should consult COA for exact batch sequence). Total ~32 amino acids.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3.800 Da (dependendo da sequ\u00eancia exata do MRP)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">pept\u00eddeo quim\u00e9rico de ~32 res\u00edduos \u2014 MF aproximada derivada da sequ\u00eancia C<sub>173<\/sub>H<sub>278<\/sub>N<sub>52<\/sub>O<sub>43<\/sub>S; publicado MW ~3.800 Da (dependendo do ligador pept\u00eddico exato de resid\u00eancia na membrana; consulte o COA do lote).<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Lise seletiva de membrana em c\u00e9lulas tumorais<\/strong>. (1) PNC-27 se liga <strong>HDM2<\/strong> na membrana plasm\u00e1tica de c\u00e9lulas cancer\u00edgenas. C\u00e9lulas normais expressam HDM2 apenas no n\u00facleo (onde ubiquitina e degrada p53 para controlar os n\u00edveis de p53); c\u00e9lulas cancer\u00edgenas expressam HDM2 anormalmente na superf\u00edcie celular \u2014 um marcador espec\u00edfico de tumor. (2) Uma vez ligado, o dom\u00ednio do pept\u00eddeo de resid\u00eancia na membrana (MRP) se insere na bicamada lip\u00eddica. (3) A multimeriza\u00e7\u00e3o das mol\u00e9culas de PNC-27 ligadas cria poros na membrana \u2192 morte celular necr\u00f3tica r\u00e1pida em minutos a horas. O mecanismo \u00e9 lise necr\u00f3tica da membrana (N\u00c3O apoptose cl\u00e1ssica) \u2014 distinguindo PNC-27 de pept\u00eddeos anticancer\u00edgenos via caspase.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Seletividade para C\u00e9lulas Tumorais<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Published studies has demonstrated selective cancer-cell killing in pancreatic adenocarcinoma, AML and ALL leukaemia, breast cancer, prostate cancer, melanoma, and other tumour models \u2014 with sparing of matched normal-cell controls that lack surface HDM2 expression.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA dispon\u00edvel mediante solicita\u00e7\u00e3o); massa confirmada por MALDI-TOF no MW espec\u00edfico da quimera.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C a curto prazo, \u221220 \u00b0C a longo prazo. Reconstitu\u00eddo: 2\u20138 \u00b0C, use em at\u00e9 30 dias. Evite ciclos repetidos de congelamento-descongelamento.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Lise de Membrana Direcionada a HDM2<\/h2>\n<p>PNC-27 foi desenvolvido pelo grupo Bowne \/ Pinto \/ Michl \/ Rauschmayer no Albert Einstein College of Medicine como um exemplo de <strong>design de f\u00e1rmaco pept\u00eddico quim\u00e9rico<\/strong> aplicado \u00e0 oncologia \u2014 emparelhando um dom\u00ednio de direcionamento tumoral (a h\u00e9lice de liga\u00e7\u00e3o a HDM2 derivada da p53) com um dom\u00ednio gen\u00e9rico de a\u00e7\u00e3o letal (o pept\u00eddeo de resid\u00eancia na membrana). A l\u00f3gica do design:<\/p>\n<ul>\n<li><strong>HDM2 como marcador de superf\u00edcie espec\u00edfico de tumor<\/strong> \u2014 Bowne, Michl et al. descobriram que o HDM2 (o hom\u00f3logo humano do MDM2, normalmente uma E3 ligase nuclear que ubiquitina a p53 para degrada\u00e7\u00e3o) \u00e9 expresso anomalamente na superf\u00edcie da membrana plasm\u00e1tica de praticamente todas as linhagens de c\u00e9lulas cancer\u00edgenas que testaram, mas n\u00e3o em c\u00e9lulas normais correspondentes. Isso torna o HDM2 de membrana um marcador de superf\u00edcie de c\u00e9lulas cancer\u00edgenas quase universal.<\/li>\n<li><strong>h\u00e9lice p53(12-26) como ligante de liga\u00e7\u00e3o a HDM2<\/strong> \u2014 Os res\u00edduos 12\u201326 do dom\u00ednio de transativa\u00e7\u00e3o da p53 (PPLSQETFSDLWKLL) formam uma \u03b1-h\u00e9lice que \u00e9 a interface natural de liga\u00e7\u00e3o ao HDM2; o HDM2 normalmente captura essa h\u00e9lice para ubiquitinar a p53. O PNC-27 empresta essa h\u00e9lice como dom\u00ednio de direcionamento. O pept\u00eddeo se liga ao HDM2 no mesmo local que os inibidores de HDM2 de pequenas mol\u00e9culas do tipo nutlin, mas com a geometria natural da h\u00e9lice da p53.<\/li>\n<li><strong>Pept\u00eddeo de resid\u00eancia na membrana (MRP) como dom\u00ednio de a\u00e7\u00e3o letal<\/strong> \u2014 Uma vez ancorado ao HDM2 de superf\u00edcie, o dom\u00ednio MRP C-terminal se insere na bicamada lip\u00eddica. A geometria anfip\u00e1tica do MRP, mais a oligomeriza\u00e7\u00e3o das mol\u00e9culas de PNC-27 ligadas na superf\u00edcie da c\u00e9lula cancer\u00edgena, produz poros transmembrana em minutos.<\/li>\n<li><strong>Morte celular necr\u00f3tica<\/strong> \u2014 A forma\u00e7\u00e3o de poros causa perda r\u00e1pida da integridade da membrana, lise osm\u00f3tica e morte celular necr\u00f3tica \u2014 distinta da cascata apopt\u00f3tica lenta desencadeada por inibidores cl\u00e1ssicos de HDM2 de pequenas mol\u00e9culas (que funcionam estabilizando a p53 para permitir a apoptose mediada por p53 a jusante). O mecanismo necr\u00f3tico do PNC-27 \u00e9 r\u00e1pido (minutos a horas) e n\u00e3o depende de p53 funcional na c\u00e9lula tumoral \u2014 tornando-o potencialmente \u00fatil em tumores com muta\u00e7\u00e3o em p53 onde inibidores do tipo nutlin s\u00e3o inativos.<\/li>\n<li><strong>Poupan\u00e7a de c\u00e9lulas normais<\/strong> \u2014 Normal cells lack surface HDM2 (HDM2 is normally only nuclear), so PNC-27 has no anchoring site on normal cells and does not produce significant membrane-lysis. Published studies has demonstrated this selectivity in matched cancer-vs-normal cell pair comparisons across multiple tumour types.<\/li>\n<\/ul>\n<h2>Published Evidence<\/h2>\n<ul>\n<li><strong>Design de f\u00e1rmaco oncol\u00f3gico pept\u00eddico quim\u00e9rico<\/strong> \u2014 exemplo can\u00f4nico de quimera dom\u00ednio-homing + dom\u00ednio-killer aplicada ao c\u00e2ncer (junto com <a href=\"https:\/\/medsbase.com\/pt-br\/adipotide-ftpp\/\">Adipotide\/FTPP<\/a> no mesmo paradigma)<\/li>\n<li><strong>Pancreatic cancer studies<\/strong> \u2014 tipo de tumor mais publicado para estudos de efic\u00e1cia do PNC-27 (adenocarcinoma pancre\u00e1tico tem alta express\u00e3o de HDM2 e \u00e9 convencionalmente dif\u00edcil de tratar)<\/li>\n<li><strong>Leukaemia studies<\/strong> \u2014 AML and ALL cell-line studies; combination with conventional chemotherapeutics<\/li>\n<li><strong>p53-mutant cancer studies<\/strong> \u2014 ao contr\u00e1rio dos inibidores de HDM2 do tipo nutlin (que requerem p53 funcional), o PNC-27 \u00e9 mecanicamente ativo em tumores com muta\u00e7\u00e3o no p53 \u2014 ferramenta \u00fatil para esse subconjunto<\/li>\n<li><strong>Surface HDM2 biology studies<\/strong> \u2014 a liga\u00e7\u00e3o do PNC-27 \u00e9 um dos ensaios can\u00f4nicos para detec\u00e7\u00e3o de HDM2 de superf\u00edcie na biologia de c\u00e9lulas cancer\u00edgenas<\/li>\n<li><strong>Farmacologia da morte celular necr\u00f3tica vs apopt\u00f3tica<\/strong> \u2014 useful reference compound for membrane-lysis vs caspase-cascade dissection in cell-death studies<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre pept\u00eddeos quim\u00e9ricos disruptores de membrana direcionados a tumores, consulte <a href=\"https:\/\/medsbase.com\/pt-br\/adipotide-ftpp\/\">Adipotide\/FTPP<\/a> (quimera de perda de gordura por apoptose direcionada a vasos \u2014 mesmo paradigma homing+killer aplicado ao tecido adiposo). Veja tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-br\/bpc-157\/\">BPC-157<\/a> (pept\u00eddeo de recupera\u00e7\u00e3o), <a href=\"https:\/\/medsbase.com\/pt-br\/tb-500\/\">TB-500<\/a> (pept\u00eddeo de recupera\u00e7\u00e3o), e o completo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a>. <\/p>\n<h2>Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong> \u2014 entry protocols, dose-titration in tumour-cell culture<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong> \u2014 extended protocols, large-cohort murine xenograft studies; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p>Armazene os frascos liofilizados a 2\u20138 \u00b0C; congele n\u00e3o abertos a \u221220 \u00b0C para armazenamento de longo prazo. Reconstitua com \u00e1gua bacteriost\u00e1tica (1,0 mL por frasco de 5 mg \u2192 5 mg\/mL; 1,0 mL por frasco de 10 mg \u2192 10 mg\/mL). Agite suavemente. Armazene reconstitu\u00eddo a 2\u20138 \u00b0C, use dentro de 30 dias. Evite ciclos repetidos de congelamento-descongelamento. O dom\u00ednio MRP anfip\u00e1tico pode apresentar espuma transit\u00f3ria na reconstitui\u00e7\u00e3o inicial \u2014 deixe assentar antes do uso. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>Como o PNC-27 \u00e9 diferente dos inibidores de HDM2 de pequenas mol\u00e9culas, como a nutlina?<\/h3>\n<p>Os inibidores de HDM2 de pequenas mol\u00e9culas (nutlina-3, idasanutlina, MI-77301) competem com o p53 pelo mesmo s\u00edtio de liga\u00e7\u00e3o nuclear-HDM2 \u2014 estabilizando o p53 para permitir apoptose downstream. Eles requerem p53 funcional no tumor para funcionar. O PNC-27 age de maneira completamente diferente: ele se liga <em>superf\u00edcie<\/em> ao HDM2 (expresso anormalmente em c\u00e9lulas cancer\u00edgenas) e desencadeia lise membranar necr\u00f3tica sem exigir p53 funcional. O PNC-27 \u00e9, portanto, ativo em tumores com muta\u00e7\u00e3o no p53 onde os inibidores do tipo nutlina n\u00e3o s\u00e3o. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>In-vitro tumour-cell cytotoxicity assays typically use 1\u201350 \u00b5M PNC-27 in culture medium. Murine xenograft has used 5\u201320 mg\/kg IP, daily or every-other-day, for 2\u20134 weeks. Users should consult Bowne, Pinto, Michl, Rauschmayer published work for protocol-specific guidance. <\/p>\n<h3>O PNC-27 est\u00e1 em ensaios cl\u00ednicos?<\/h3>\n<p>PNC-27 remains a preclinical studies compound; no formal Phase I\/II\/III human clinical trials have been completed to date. It continues to be cited as the canonical example of HDM2-surface-targeted chimeric peptide drug design. <\/p>\n<h3>Can PNC-27 be combined with chemotherapy in studies?<\/h3>\n<p>Yes \u2014 published studies has examined PNC-27 in combination with gemcitabine (pancreatic cancer), cytarabine (AML), and other conventional chemotherapeutics, with broadly additive or super-additive cytotoxicity reported. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Chimeric \/ Targeted Peptides<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/adipotide-ftpp\/\"><strong>Adipotide\/FTPP<\/strong><\/a> \u2014 Quimera de apoptose direcionada vascular (homing em tecido adiposo + D(KLAKLAK)\u2082 killer) \u2014 mesmo paradigma homing+killer<\/li>\n<li><a href=\"\/pt-br\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Pentadecapept\u00eddeo de recupera\u00e7\u00e3o e reparo tecidual<\/li>\n<li><a href=\"\/pt-br\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Fragmento de Timosina Beta-4, recupera\u00e7\u00e3o de tecidos moles<\/li>\n<li><a href=\"\/pt-br\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper-binding tripeptide, skin and connective tissue studies<\/li>\n<li><a href=\"\/pt-br\/peptides\/\"><strong>Cat\u00e1logo completo de pept\u00eddeos<\/strong><\/a><\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 ~32 aa pept\u00eddeo quim\u00e9rico \u2014 h\u00e9lice de liga\u00e7\u00e3o HDM2 p53(12-26) + pept\u00eddeo de resid\u00eancia em membrana<br \/>\n\u2705 Liga-se ao HDM2 an\u00f4malo na superf\u00edcie de c\u00e9lulas cancerosas \u2192 lise da membrana (n\u00e3o apoptose cl\u00e1ssica)<br \/>\n\u2705 Morte necr\u00f3tica seletiva de c\u00e9lulas tumorais; poupa c\u00e9lulas normais (sem HDM2 na superf\u00edcie)<br \/>\n\u2705 Ativo em tumores com muta\u00e7\u00e3o p53 onde inibidores do tipo nutlin falham<br \/>\n\u2705 Design de pept\u00eddeo quim\u00e9rico Bowne\/Pinto\/Michl Albert Einstein; MW ~3.800 Da<\/p>\n<p><strong>PNC-27<\/strong> contains synthetic p53-HDM2 chimeric peptide.<\/p>","protected":false},"featured_media":71524,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6530,6506,6528,6531,6527,6526,6494,6529],"class_list":["post-71484","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cancer-research-peptide","product_tag-chimeric-peptide","product_tag-hdm2-inhibitor","product_tag-membrane-lysis-peptide","product_tag-p53-peptide","product_tag-pnc-27","product_tag-research-peptide","product_tag-tumour-targeted-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71484"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71524"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71484"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71484"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71484"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}